Oxyresveratrol powered by LipodisqTM Sterile Solution
Product Code:
IAX-700-104
IAX-700-104
Regulatory Status:
RUO
RUO
Shipping:
AMBIENT
AMBIENT
Storage:
Short term: +4°C. Long term: +4°C
Short term: +4°C. Long term: +4°C
No additional charges, what you see is what you pay! *
| Code | Size | Price |
|---|
| IAX-700-104-L001 | 1 ml | £197.00 |
Quantity:
Prices exclude any Taxes / VAT
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: Switzerland.
Typical lead time: 7-10 working days.
Contact us for more accurate information.
Typical lead time: 7-10 working days.
Contact us for more accurate information.
- Further Information
- Documents
- References
- Show All
Further Information
Alternate Names/Synonyms:
trans-2',3,4',5-Tetramethoxystilbene
Appearance:
Light amber coloured clear aqueous solution
Biological Activity:
Discoidal nano-particles can incorporate hydrophobic, poorly water-soluble compounds, such as lipids, lipoproteins and glycolipids. - Cell culture tested (human macrophage cell line) (MTT). - Recommended starting dilution: 1:200 or higher. - Optimal working concentrations depend on the applications and need to be determined. - Published procedures using Lipodisq formulations (Curcumin and IAXO TLR4 antagonists) in vivo rodent models at 3-10mg/kg. Recommended route of administration is subcutaneous (s.c.) with oral or nasal application as a possible alternative, which needs to be optimized.
CAS:
29700-22-9
Concentration:
1mg/ml (0.1% w/vol)
EClass:
32160000
Form (Short):
liquid
Formulation:
Liquid, detergent-free discoidal nano-formulation made of styrene-maleic acid lipid particles (SMALP), lecithin and sterile water.
GHS Symbol:
GHS07
Handling Advice:
Keep sterile. Avoid skin and eye contact.
Hazards:
H319
InChi:
InChI=1S/C14H12O4/c15-11-4-3-10(14(18)8-11)2-1-9-5-12(16)7-13(17)6-9/h1-8,15-18H/b2-1-
InChiKey:
PDHAOJSHSJQANO-UPHRSURJSA-N
Long Description:
Chemical. CAS: 29700-22-9. Formula: C14H12O4. MW: 244.2. Oxyresveratrol Lipodisq Sterile Solution is a ready-to-use nano-formulated aqueous solution. Oxyresveratrol is a naturally occurring analog of resveratrol. Potent antioxidant and free-radical scavenger. Shown to have neuroprotective activity against cerebral ischemia and against traumatic injury. Apoptosis inhibitor in transient cerebral ischemia. Inhibits viral DNA replication and late viral protein synthesis. Has depigmenting effects by effectively inhibiting tyrosinase activity, which catalyzes the rate-limiting step in synthesizing melanin pigments. Has anti-inflammatory properties based on inhibition of iNOS expression through down-regulation of NF-kB binding activity and significant inhibition of COX-2 activity. Anti-hyperlipidemic agent. Oxyresveratrol Lipodisq is based on a nanoparticle (11-40nm) drug delivery system comprising a discoidal phospholipid bilayer membrane stabilized by a chaperone molecule annulus. Internal properties of the phospholipid membrane support the disposition and stabilization of drug molecule candidates and preserve the native conformation of membrane molecules. The resulting encapsulated actives are rendered water-soluble and specialized for intra-cellular penetration/delivery via endosomal uptake mechanisms. Lipodisq solutions show a good safety profile and are suitable for in vitro and in vivo investigations.
MDL:
MFCD11974969
Molecular Formula:
C14H12O4
Molecular Weight:
244.2
Other data:
Lipodisq™ technology is covered by one or more of the following patents owned by Malvern Cosmeceutics Limited: AU2006253886, CA2611144, CN101184473B, EP1890675, GB2426703, IN261468, JP5142898, US8623414 and WO/2021/005340A1 pending. The purchaser is licensed under those patents to use these assemblies for the purpose of research and development only, but not for the purpose of delivery of agents for clinical use to humans or veterinary use to animals for therapeutic, diagnostic or prophylactic purposes, which uses are specifically prohibited.
Package Type:
Vial
Precautions:
P305, P351, P338
Product Description:
Oxyresveratrol Lipodisq Sterile Solution is a ready-to-use nano-formulated aqueous solution. Oxyresveratrol is a naturally occurring analog of resveratrol. Potent antioxidant and free-radical scavenger. Shown to have neuroprotective activity against cerebral ischemia and against traumatic injury. Apoptosis inhibitor in transient cerebral ischemia. Inhibits viral DNA replication and late viral protein synthesis. Has depigmenting effects by effectively inhibiting tyrosinase activity, which catalyzes the rate-limiting step in synthesizing melanin pigments. Has anti-inflammatory properties based on inhibition of iNOS expression through down-regulation of NF-kB binding activity and significant inhibition of COX-2 activity. Anti-hyperlipidemic agent. Oxyresveratrol Lipodisq is based on a nanoparticle (11-40nm) drug delivery system comprising a discoidal phospholipid bilayer membrane stabilized by a chaperone molecule annulus. Internal properties of the phospholipid membrane support the disposition and stabilization of drug molecule candidates and preserve the native conformation of membrane molecules. The resulting encapsulated actives are rendered water-soluble and specialized for intra-cellular penetration/delivery via endosomal uptake mechanisms. Lipodisq solutions show a good safety profile and are suitable for in vitro and in vivo investigations.
Purity:
>95% (HPLC)
Signal Word:
Warning
SMILES:
OC1=CC(O)=C(C=CC2=CC(O)=CC(O)=C2)C=C1
Solubility Chemicals:
Soluble in water, PBS, Tris and other physiological solutions as formulated in a proprietary, thermostable, aqueous lipid nanoparticulate formulation (Lipodisq).
Transportation:
Non-Hazardous
UNSPSC Category:
Biochemical Reagents
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 1 year after receipt when stored at +4°C.
Documents
References
Oxyresveratrol Supplementation to C57bl/6 Mice Fed with a High-Fat Diet Ameliorates Obesity-Associated Symptoms: H.Y. Tan, et al.; 9, 147 Nutrients (2017) | Oxyresveratrol Inhibits R848-Induced Pro-Inflammatory Mediators Release by Human Dendritic Cells Even When Embedded in PLGA Nanoparticles: S.C. Gaglio, et al.; Molecules 26, 2106 (2021) | Oxyresveratrol Ameliorates Dextran Sulfate Sodium-Induced Colitis in Rats by Suppressing Inflammation: J. Yeom, et al.; Molecules 26, 2630 (2021) | Oxyresveratrol: Sources, Productions, Biological Activities, Pharmacokinetics, and Delivery Systems: K. Likhitwitayawuid; Molecules 26, 4212 (2021) | Oxyresveratrol-Loaded PLGA Nanoparticles Inhibit Oxygen Free Radical Production by Human Monocytes: Role in Nanoparticle Biocompatibility: M. Donini, et al.; Molecules 26, 4351 (2021) | General References for Lipodisq™ Technology: | Responsive Hydrophobically Associating Polymers: A Review of Structure and Properties: S.R. Tonge & B.J. Tighe; Adv. Drug Deliv. Rev. 53, 109 (2001) | Detergent-free formation and physico-chemical characterization of nanosized lipidpolymer complexes: Lipodisq; M.C. Orwick, et al.; Angew. Chem. 51, 4653 (2012) | Physicochemical Characterization, Toxicity and In Vivo Biodistribution Studies of a Discoidal, Lipid-Based Drug Delivery Vehicle: Lipodisq Nanoparticles Containing Doxorubicin: M.L. Torgersen, et al.; J. Biomed. Nanotechnol. 16, 41 (2020) | Applications of Synthetic Polymer Discoidal Lipid Nanoparticles to Biomedical Research: M. Tanaka; Chem. Pharm. Bull. 70, 507 (2022) | Mechanisms of Formation, Structure, and Dynamics of Lipoprotein Discs Stabilized by Amphiphilic Copolymers: A Comprehensive Review: P.S. Orekhov, et al.; Nanomaterials 12, 361 (2022)